9 completed, 6 terminated, 1 active not recruiting, 1 no longer available. 7 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 4 | 2 | Completed 2 |
Follow Carcinoma, Large Cell: new trials by email Literature Review of Carcinoma, Large Cell trials Research Report on Carcinoma, Large Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | Maia Biotechnology | 300 | 2025-12-08 | 2026-01-12 |
| THIO Sequenced With Cemiplimab in Advanced NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Maia Biotechnology | 227 | 2022-06-08 | 2026-09-16 |
| A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination - Lung Cancer, Small Cell Lung Cancer | Completed | Creative Biosciences (Guangzhou) Co., Ltd. | 1564 | 2022-02-25 | 2025-03-21 | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Brigatinib, Crizotinib - Non-small Cell Lung Cancer, Lung Cancer | Phase 3 | Completed | Ariad Pharmaceuticals | 275 | 2016-05-26 | 2021-08-20 |
| Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly nab-paclitaxel, Carboplatin - Non-Small Cell Lung Cancer, Carcinoma | Phase 4 | Completed | Celgene | 143 | 2014-06-09 | 2018-09-24 |
| Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy) - Non-small-cell Lung Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 21 | 2012-08-01 | 2017-12-07 |
| Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer Temoporfin - Carcinoma, Non-Small-Cell-Lung | Phase 1 | Withdrawn | University of Arkansas | 2012-07-01 | 2014-01-15 | |
| -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer PF-02341066/PF-00299804 - Carcinoma, Non-Small Cell Lung, Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2011-09-01 | 2019-12-17 |
| A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 226 | 2011-05-01 | 2014-05-19 |
| RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation RAD001, Paclitaxel, Carboplatin - Carcinoma, Large Cell, Neuroendocrine Tumors | Phase 4 | Completed | Novartis Pharmaceuticals | 49 | 2011-04-01 | 2016-03-30 |
| A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Docetaxel, Oxaliplatin - Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous | Phase 2 | Unknown | Korean South West Oncology Group | 35 | 2011-02-01 | 2011-12-22 |
| Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer CP 751,871 (Figitumumab), Erlotinib - Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Pfizer | 583 | 2008-05-01 | 2013-07-24 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology CP-751,871 (Figitumumab), Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Carcinoma, Adenosquamous | Phase 3 | Terminated | Pfizer | 681 | 2008-04-01 | 2014-01-13 |
| Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) Temozolomide - Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 53 | 2008-03-04 | 2017-06-07 |
| ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures ZD6474 (vandetanib), Best Supportive Care - Non-Small-Cell Lung Carcinoma | Phase 3 | Completed | Genzyme, a Sanofi Company | 1140 | 2006-11-01 | 2016-09-30 |
| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer Motexafin gadolinium and pemetrexed - Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | Pharmacyclics LLC. | 74 | 2006-06-01 | 2013-10-31 |
| A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) Motexafin Gadolinium Injection - Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic | Phase 1 | Completed | Pharmacyclics LLC. | 36 | 2004-11-01 | 2009-04-03 |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 54 | 2003-11-01 | 2020-05-28 |
| An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer EP2101 - Carcinoma, Non-Small-Cell Lung, Lung Neoplasm | Phase 1 | Completed | Epimmune | 18 | 2003-01-01 | 2010-03-24 |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer Brigatinib - Non-small Cell Lung Cancer, Lung Cancer | No longer available | Ariad Pharmaceuticals | 2018-02-06 |
Carcinoma, Non-Small-Cell Lung (19) · Carcinoma, Squamous Cell (18) · Lung Neoplasms (12) · Adenocarcinoma (11) · Carcinoma (6) · Adenocarcinoma of Lung (3) · Carcinoma, Adenosquamous (2) · Bronchitis (1) · Bronchitis, Chronic (1) · Carcinoma, Bronchogenic (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Pneumonia (1) · Pulmonary Disease, Chronic Obstructive (1)
Lung Diseases (20) · Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Glandular and Epithelial (20) · Respiratory Tract Diseases (20) · Respiratory Tract Neoplasms (20) · Thoracic Neoplasms (20) · Bronchial Neoplasms (19) · Neoplasms (19) · Carcinoma, Bronchogenic (18) · Neoplasms, Squamous Cell (18) · Carcinoma (14) · Lung Neoplasms (8) · Adenocarcinoma (3) · Disease Attributes (2)
Carboplatin (3) · Docetaxel (3) · Paclitaxel (2) · alpha-2'-deoxythioguanosine (2) · brigatinib (2) · cemiplimab (2) · figitumumab (2) · motexafin gadolinium (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Crizotinib (1) · Erlotinib Hydrochloride (1) · Everolimus (1) · Gemcitabine (1) · Oxaliplatin (1)
Ariad Pharmaceuticals (2) · Maia Biotechnology (2) · Pfizer (2) · Pharmacyclics LLC. (2) · Celgene (1) · Creative Biosciences (Guangzhou) Co., Ltd. (1) · Epimmune (1) · Genzyme, a Sanofi Company (1) · Infinity Pharmaceuticals, Inc. (1) · Korean South West Oncology Group (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · NewLink Genetics Corporation (1) · Novartis Pharmaceuticals (1)
United States (15) · Taiwan (7) · South Korea (6) · Australia (4) · Canada (4) · France (4) · Germany (4) · Hungary (4) · Italy (4) · Poland (4) · Spain (4) · Austria (3) · Bulgaria (3) · Hong Kong (3) · Romania (3)
Arun Rajan, M.D. (2) · Joe Y. Chang, MD, MS, PHD (1) · Laiyu Liu, PhD (1) · Lei Zheng, PhD (1) · Martin Edelman, MD (1) · Mary E Meek, MD (1) · Sang Byung Bae, M.D. (1) · Teng Jin Ong (1) · Tess Schmalbach, MD (1) · Victor Zaporojan, MD (1) · Victor Zaporojan, Medical Doctor (1)
PMID 24888810, PMID 25069747, PMID 25395283, PMID 25881079, PMID 28501139, PMID 28535181, PMID 30280657, PMID 32780660, PMID 38468440, PMID 39707229, PMID 41332393, PMID 41410381, PMID 41740899
2015 (1), 2023 (1), P01CA021239 (1)